Pharma Mar, S.A. (PHMMF)
PHMMF Stock Price Chart
Explore Pharma Mar, S.A. interactive price chart. Choose custom timeframes to analyze PHMMF price movements and trends.
PHMMF Company Profile
Discover essential business fundamentals and corporate details for Pharma Mar, S.A. (PHMMF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Feb 2016
Employees
500.00
Website
https://www.pharmamar.comCEO
Jose Maria Fernandez Sousa-Faro
Description
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
PHMMF Financial Timeline
Browse a chronological timeline of Pharma Mar, S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 27 Oct 2025
Earnings released on 30 Jul 2025
EPS came in at $1.59 surpassing the estimated $0.04 by +4.40K%, while revenue for the quarter reached $66.40M , beating expectations by +90.80%.
Dividend declared on 25 Jun 2025
A dividend of $0.93 per share was announced, adjusted to $0.93. The dividend was paid on 27 Jun 2025.
Earnings released on 24 Apr 2025
EPS came in at -$0.25 falling short of the estimated $0.34 by -173.41%, while revenue for the quarter reached $42.60M , beating expectations by +8.12%.
Earnings released on 26 Feb 2025
EPS came in at $1.10 surpassing the estimated $1.00 by +10.00%, while revenue for the quarter reached $50.08M , beating expectations by +23.55%.
Earnings released on 29 Oct 2024
EPS came in at $0.24 surpassing the estimated $0.23 by +6.35%, while revenue for the quarter reached $50.07M , missing expectations by -1.76%.
Earnings released on 30 Jul 2024
EPS came in at $0.08 surpassing the estimated $0.01 by +604.01%, while revenue for the quarter reached $46.10M , missing expectations by -1.63%.
Dividend declared on 12 Jun 2024
A dividend of $0.70 per share was announced, adjusted to $0.70. The dividend was paid on 14 Jun 2024.
Earnings released on 23 Apr 2024
EPS came in at $0.14 surpassing the estimated -$0.08 by +286.81%, while revenue for the quarter reached $40.79M , beating expectations by +10.63%.
Earnings released on 28 Feb 2024
EPS came in at -$0.43 falling short of the estimated $0.09 by -581.46%, while revenue for the quarter reached $44.55M , missing expectations by -3.44%.
Earnings released on 30 Sept 2023
EPS came in at $0.09 falling short of the estimated $0.23 by -61.63%, while revenue for the quarter reached $39.51M , beating expectations by +6.99%.
Earnings released on 30 Jun 2023
EPS came in at $0.30 surpassing the estimated $0.04 by +598.83%, while revenue for the quarter reached $50.41M , beating expectations by +43.31%.
Dividend declared on 7 Jun 2023
A dividend of $0.70 per share was announced, adjusted to $0.70. The dividend was paid on 9 Jun 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.08 falling short of the estimated $0.22 by -60.92%, while revenue for the quarter reached $36.94M , missing expectations by -25.33%.
Earnings released on 31 Dec 2022
EPS came in at $0.08 , while revenue for the quarter reached $59.18M .
Earnings released on 30 Sept 2022
EPS came in at $0.71 falling short of the estimated $0.97 by -27.41%, while revenue for the quarter reached $39.03M , beating expectations by +0.05%.
Dividend declared on 13 Jul 2022
A dividend of $0.66 per share was announced, adjusted to $0.65. The dividend was paid on 15 Jul 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.75 , while revenue for the quarter reached $50.47M , beating expectations by +81.72%.
Earnings released on 31 Mar 2022
EPS came in at $1.35 , while revenue for the quarter reached $58.83M , beating expectations by +20.01%.
Earnings released on 31 Dec 2021
EPS came in at $2.40 , while revenue for the quarter reached $97.37M , beating expectations by +218.47%.
Earnings released on 30 Sept 2021
EPS came in at $0.74 , while revenue for the quarter reached $52.52M .
Earnings released on 30 Jun 2021
EPS came in at $1.25 , while revenue for the quarter reached $56.27M , beating expectations by +79.99%.
Dividend declared on 28 Apr 2021
A dividend of $0.73 per share was announced, adjusted to $0.73. The dividend was paid on 30 Apr 2021.
Earnings released on 31 Mar 2021
EPS came in at $1.57 , while revenue for the quarter reached $60.29M .
Earnings released on 31 Dec 2020
EPS came in at $0.42 , while revenue for the quarter reached $58.63M .
Earnings released on 30 Sept 2020
EPS came in at $1.12 , while revenue for the quarter reached $62.28M .
PHMMF Stock Performance
Access detailed PHMMF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.